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- 255 VOCs, with masses ranging from 30 to 431 Dalton have been identified in the exhaled breath.
- Using a classification technique based on the ROC curve for each VOC, a set of 9 biomarkers discriminating 
the presence of CRC from healthy volunteers was obtained, showing an average recognition rate of 81.94%, a 
sensitivity of 87.04% and specificity of 76.85%.
- Although these results are quite promising, we have discovered  that some of these variables  present a 
temporal evolution which may be  produced by contaminants in the environment. Therefore these results 
should  be taken with caution.
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CRC is one of the most common cancers in the Western world, with high incidence and mortality. Slow
progression from adenoma to carcinoma and high patient survival in case of early detection makes CRC an ideal
candidate for screening. Screening programms for CRC are being developed throughout the Western World with
participation rates under 60% in the average-risk population using the recommended tests (gFoBT or endoscopic
techniques).
There are somes evidence supporting a different pattern of VOCs in breath in cancer patients, due to the different
metabolism of cancer cells producing different VOCs, that may have expression in breath. Actually, dogs trained
for scent discrimination were able to discriminate CRC patients from healthy controls (Sonoda et al. 2010).
Mass spectrometry devices have been devoloped to identify the individual VOCs present in breath samples, but
there are many methodological differences between the studies without validated results. Results in lung and
breast cancer using this approach are promising (Phillips et al, 1999; Patterson et al 2011), but there is few data
about its potential role in CRC diagnosis.
Along with this, breath analysis of VOCs could be an easy and very acceptable test to increase the efficiency of a
population-based screening program.
Background: Analysis of exhaled volatile organic compounds (VOCs) in breath is an emerging approach for cancer diagnosis,
but little is known about its potential use as a biomarker for colorectal cancer (CRC). We investigated whether a combination of
VOCs could distinct CRC patients from healthy volunteers.
Methods: In a pilot study, we prospectively analyzed breath exhalations of 38 CRC patient and 43 healthy controls all scheduled
for colonoscopy, older than 50 in the average-risk category. The samples were ionized and analyzed using a Secondary
ElectroSpray Ionization (SESI) coupled with a Time-of-Flight Mass Spectrometer (SESI-MS). After a minimum of 2 hours fasting,
volunteers deeply exhaled into the system. Each test requires three soft exhalations and takes less than ten minutes. No breath
condensate or collection are required and VOCs masses are detected in real time, also allowing for a spirometric profile to be
analyzed along with the VOCs. A new sampling system precludes ambient air from entering the system, so background
contamination is reduced by an overall factor of ten. Potential confounding variables from the patient or the environment that
could interfere with results were analyzed.
Results: 255 VOCs, with masses ranging from 30 to 431 Dalton have been identified in the exhaled breath. Using a classification
technique based on the ROC curve for each VOC, a set of 9 biomarkers discriminating the presence of CRC from healthy
volunteers was obtained, showing an average recognition rate of 81.94%, a sensitivity of 87.04% and specificity of 76.85%.
Conclusions: A combination of cualitative and cuantitative analysis of VOCs in the exhaled breath could be a powerful diagnostic
tool for average-risk CRC population. These results should be taken with precaution, as many endogenous or exogenous
contaminants could interfere as confounding variables. On-line analysis with SESI-MS is less time-consuming and doesn’t need
sample preparation. We are recruiting in a new pilot study including breath cleaning procedures and spirometric analysis
incorporated into the postprocessing algorithms, to better control for confounding variables.
SESI-based analysis shows high sensitivity for the discovery of candidate biomarkers in breath and allows on-line
analysis without a pre-concentration step.
We couldn´t find in breath obvious differences in the pattern of VOCs between CRC patients and healthy controls.
Species coming from the inhaled air and those related to the long term distribution seem to be the main
confounding variable to control.
Despite these, overall sensitivity and specificity results are encouraging to pursue investigating the potential use
of breath analysis for detecting CRC.
We are recruiting in a new pilot study including breath cleaning procedures, random distribution of patients and
spirometric analysis incorporated into the postprocessing algorithms, to better control for confounding variables.
Demographics: Prospectively enrolled 38 CRC patients (all AJCC stages) and 43 healthy volunteers, diagnosed 
with colonoscopy.
Confounding variables: potential interferents were recorded before sampling (comorbidities, smoking, food, 
medications, cosmetics, enviromental exposure, family history and other CRC risk factors) using a questionnaire.
Breath sample: after 2 hours fasting volunteers exhaled into the system directly, without collection of breath in 
any recipient.
Mass spectrometry system: Secondary ElectroSpray Ionization (SESI) coupled with a Time-of-Flight Mass 
Spectrometer (SESI-MS).
1.Ion Source: SESI (Secondary ElectroSpray Ionizer) is a soft ionization technique at atmospheric pressure 
(API) where a electrospray cloud produces OH-ions that ionize polar molecules.
Introducing humid air and improving fluid configuration reduces required fluid rate and improves ionization 
efficiency allowing eliminating preconcentration step and on-line analysis (Martínez-Lozano & Fernandez de la 
Mora, 2007).
2.Mass analyzer: Quadruple time-of-flight mass spectrometer (QqTOF-MS).
3.Data analysis: Features: Area under the peak  from spectrum  (AUP). Relative concentrations (Division by the 
sum of all AUPS). Preprocessing: AUP(breath)-AUP(background). Classifier (for each feature): Optimal ROC 
point. Fusion several classifiers: Majority voting. Feature selection: Forward selection. Validation: Leave-One-
Out.
4.VOCs identification: The obtained data was compared with the Metlin Database to identify the candidate 
species using a tolerance of 0.01 Da for the average mass.
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To determine whether a combination of VOCs could distinct CRC patients from healthy volunteers. It was our 
purpose to provide a framework for a new pilot study in this area.
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VOC Mass interval Specificity Sensitivity recognition rate Candidate species
1 149.9775 150.0575 0.6389 0.7407 0.6898 Non identified
2 233.0924 233.2167 0.4722 0.9352 0.7037 Valerenic acid
3 178.9123 179.0030 0.6852 0.8148 0.7500 Non identified
4 99.9526 99.9896 0.6204 0.8704 0.7454 Non identified
5 180.9804 181.0426 0.7963 0.7963 0.7963 2-Oxo-4-phosphonobutanoate
6 218.9237 218.9916 0.7222 0.8889 0.8056 DICAMBA 
2,4-Dichlorophenoxyacetic acid 
7 141.0003 141.0346 0.7685 0.8333 0.8009 Kojic acid, Muconic acid
8 229.0386 229.0971 0.7037 0.9167 0.8102 Non identified
9 182.9143 183.0212 0.7685 0.8704 0.8194 Phosphohydroxypyruvic acid
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